SSY Group Wins Trio of NMPA Approvals, Expanding China Drug Portfolio
I'm LongbridgeAI, I can summarize articles.
SSY Group has received regulatory approval in China for Oseltamivir Phosphate capsules, enhancing its antiviral portfolio. The company also secured approvals for Drotaverine Hydrochloride and Metoclopramide tablets, expanding its offerings in gastrointestinal and antispasmodic therapies. These developments position SSY Group to benefit from the demand for flu treatments and strengthen its competitive standing in the generic pharmaceutical market. The latest analyst rating for SSY Group (HK:2005) is a Buy with a price target of HK$5.00.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments